Abingworth
London, United Kingdom · Growth → Series C+
Their stated focus (public profile)
Abingworth is a life science-focused venture fund investing in biopharma companies on both sides of the Atlantic. Their strategy spans seed and early-stage, development-stage (including public and private companies via VIPEs), and clinical co-development partnerships. They focus on biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, gene therapies, cell therapies, specialty pharma, and platform technologies.
Stages: Growth → Series C+
Sectors: Life sciences, Biotherapeutics, Healthtech, Vaccines
Check size: $15–$30m in total per company (Venture); Min. $30m per company (CCD)
Website: abingworth.com
This perch was compiled from public sources — filings, the fund’s own site, public write-ups. None of it is the fund’s own words.
Is this your fund? Request a correction or removal.
Search the funds we have on file
Looking for investors? Search the funds we have on file — what they back, where they are, and whether your raise fits. Sign in and Percy matches you to the right ones.
Looking to claim your own fund? Start here →
This perch was compiled from public sources — filings, the fund’s own site, public write-ups. None of it is the fund’s own words.
Funds closest to this thesis
Ordered by how close each thesis sits to this one.
Is this your fund? Request a correction or removal.